21 May, 2021
HALL C
TIME Lecture Title
08:15 – 08:20 Opening Remarks: Güner Hayri Özsan (Dokuz Eylül University, Turkey), Muhlis Cem Ar (İstanbul University -Cerrahpaşa, Turkey)
08:20 – 08:30 BREAK
08:30 – 09:45 COURSE-1
COVID-19 and Immunity

Scientific Chair: İlhan Tezcan (Hacettepe University, Turkey)

Immunological Basis COVID- 19 Infection and Immunoreactivity: Gülderen Yanıkkaya (Yeditepe University, Turkey)
From Exosome Cancer Immunotherapy to COVID-19 Specıfıc VLP Vaccine Development: İhsan Gürsel (Bilkent University, Turkey)

09:45 – 10:00 BREAK
10:00 – 11:15 COURSE-2
Off the Shelf Cellular Therapies

Scientific Chair: Günhan Gürman (Ankara University, Turkey)

CAR-T Cells: Hermann Einsele (University Hospital Würzburg, Germany)
NK Cells: Tolga Sütlü (Boğaziçi University, Turkey)

11:15 – 11:30 BREAK
11:30- 12:45

COURSE-3
Monoclonal Antibody Directed Immunotherapies

Scientific Chair: Meral Beksaç (Ankara University, Turkey)

Beyond Naked Antibodies: Mark Cragg (Southampton General Hospital, UK)
Check Point Inhibitors: Fuat Hulusi Demirelli (İstanbul University -Cerrahpaşa, Turkey)

 

 

TIME HALL A HALL B
13:40 – 13:45 Opening Ceremony
Speakers: Güner Hayri Özsan (Dokuz Eylül University, Turkey), Muhlis Cem Ar (İstanbul University -Cerrahpaşa, Turkey), Şule Ünal Cangül (Hacettepe University, Turkey), Meltem Kurt Yüksel (Ankara University, Turkey), Reyhan Küçükkaya (Turkey), Neslihan Andıç (Eskişehir Osmangazi University, Turkey), Leylagül Kaynar (Erciyes University, Turkey)
13:45 – 14:00 Break
14:00-15:30 SESSION-1
MULTIPLE MYELOMA
SESSION-2
PEDIATRIC LEUKEMIAS-I
Scientific Chair: Ömür Gökmen Sevindik (Medipol University, Turkey), Pieter Sonneveld (Erasmus MC, Netherlands) 
Antibodies Upfront or at Relapse?: Pieter Sonneveld (Erasmus MC, Netherlands)
What is the Best Treatment Sequence for RRMM?: Thierry Facon (Lille University Hospital, France)
Is MRD the New Outcome in Clinical Practice?: Francesca Gay (City of Health and Science University Hospital of Turin, Italy)

Scientific Chair:  Hale Ören (Dokuz Eylül University, Turkey), Michael Dworzak (St. Anna Children’s Hospital, Austria)

Advancements of the I-BFM FLOW Network: Innovative Solutions for Diagnosis and MRD Assessment in Acute Leukemias: Michael Dworzak (St. Anna Children’s Hospital, Austria)

FLOW-MRD in the Era of BITE & CART Therapies: Alexander Popov (Federal Research and Clinical Centre, Russia)

 Towards Shaping a High-Quality Network of FLOW-MRD Labs in Turkey: Günnur Deniz (Istanbul University, Turkey)

15:30 – 16:00 Break
16:00 – 16:45

SATELLITE SYMPOSIUM

New Dimension in Efficacy: Darzalex in RRMM

Scientific Chair: Meral Beksaç (Ankara University, Turkey)
Speakers: Erdal Kurtoğlu (Antalya Training and Research Hospital, Turkey), Ömür Gökmen Sevindik (Medipol University, Turkey)

16:45 – 17:15 Break
17:15 – 18:45 SESSION-3
CHRONIC MYELOID LEUKEMIA
SESSION-4
PEDIATRIC LEUKEMIAS-II

Scientific Chair: Ahmet Emre Eşkazan (İstanbul University -Cerrahpaşa, Turkey), Susanne Saussele (University Hospital Mannheim, Germany) 

Modern CML Treatment According to the New ELN Recommendations: Mario Tiribelli (University of Udine, Italy)

Treatment Free Remission. A Goal for All CML Patients?: Susanne Saussele (University Hospital Mannheim, Germany)

New Options for Patients After 1st Line: Ahmet Emre Eşkazan (İstanbul University -Cerrahpaşa, Turkey)

Scientific Chair: Volkan Hazar (Medstar Hospital, Turkey), Fatih Okcu (Texas Children’s Hospital, USA)

Epidemiology of Late Effects in Children with Acute Lymphoblastic Leukemia: Fatih Okcu (Texas Children’s Hospital, USA)

Obesity and Metabolic Syndrome in Childhood Acute Lymphoblastic Leukemia Survivors: Kala Kamdar (Texas Children’s Hospital, USA)

Early Aging, Chronic Conditions and Biological Indicators of Aging in Childhood Acute Lymphoblastic Leukemia Survivors: Monica Gramatges (Texas Children’s Hospital, USA)

 18:45 – 19:15 Break
19:15 – 20:45 SESSION-5
INDOLENT LYMPHOMAS
Scientific Chair: Meltem Olga Akay ( Koç University , Turkey), Eva Kimby (Karolinska Institute, Sweden)
Follicular Lymphoma with Focus on Therapy: Eva Kimby (Karolinska Institute, Sweden)
Cellular Therapies for Follicular Lymphoma: Koen Van Besien (Presbyterian Hospital, USA)                                             Management of Marginal Zone Lymphoma: Catherine Thieblemont (Hôpital Saint-Louis, France)
20:45 – 21:00 Break
21:00-21:45

SATELLITE SYMPOSIUM

Carfilzomib Treatment in Relapsed/Refractory Multiple Myeloma

Scientific Chair: Tülin Tuğlular (Marmara University, Turkey)
Speaker: Joseph Mikhael (Translational Genomic Research Institute, USA)

21:45 – 22:00 Break
22:00 – 23:00 ORAL PRESENTATIONS

 

 

TIME HALL A
09:30 – 11:00 SESSION-6
ACUTE MYELOID LEUKEMIA

Scientific Chair: İnci Alacacıoğlu (Dokuz Eylül University, Turkey), Hartmut Döhner (University of Ulm, Germany)
Molecular Heterogeneity and Clonal Evolution of AML: Lars Bullinger (Charité Universitätsmedizin Berlin, Germany)
Combining New Agents with “3+7“ Chemotherapy in Fit Patients: Hartmut Döhner (University of Ulm, Germany)
New Agents for the Treatment of Older Patients: Andrew Wei (Alfred Hospital, Melbourne, Australia)

11:00 – 11:30 BREAK
11:30 – 13:00 SESSION-7
CHRONIC LYMPHOCYTIC LEUKEMIA
Scientific Chair: Fatih Demirkan (Dokuz Eylül University, Turkey)Michael Hallek (University Hospital of Cologne, Germany)
State-of-the Art First Line Therapy of CLL: Michael Hallek (University Hospital of Cologne, Germany)
Management of Relapsed CLL and Richter Transformation: Davide Rossi (Institute of Oncology Research, Switzerland)
Modelling of Response Pattern and Cloned Evolution of CLL: Othman Al-Sawaf (University Hospital of Cologne, Germany)
13:00 – 13:30 BREAK
13:30 -14:15

Abbvie | Brands of the World™ | Download vector logos and logotypesSATELLITE SYMPOSIUM
The Evolving Role of Venetoclax in the Era of Novel R/R CLL Therapies

Scientific Chair: Burhan Ferhanoğlu (Koç University, Turkey)
Speaker: Michael Hallek (University Hospital of Cologne, Germany)

14:15 – 14:45 BREAK
14:45- 16:15 SESSION-8
HODGKIN LYMPHOMA
Scientific Chair: Muhit Özcan (Ankara University, Turkey), Bastian von Tresckow (University Hospital Essen, Germany)
Firstline Treatment of HL: Paul Bröckelmann (University Hospital of Cologne, Germany)
Update on NLPHL: Dennis Eichenauer (University Hospital of Cologne, Germany)
Relapsed and Refractory HL: Innovative Therapies: Bastian von Tresckow (University Hospital Essen , Germany)
16:15 – 16:45 BREAK
16:45 – 17:30

SATELLITE SYMPOSIUM

Optimizing Outcomes for Patients with CLL in 2021: Challenging the Genetics

Scientific Chair: Ahmet Muzaffer Demir (Trakya University, Turkey)
How Biology is Informing Treatment Decisions in Firstline CLL ?: Fatih Demirkan (Dokuz Eylül University, Turkey)
Breakthrough CLL Disease Control in Relapsed  & Refractory Settings: Long Term Ibrutinib Outcomes: Önder           
      Arslan (Ankara University, Turkey)
 

17:30 – 18:00 BREAK
18:00 – 19:30 SESSION-9
ACUTE LYMPHOBLASTIC LEUKEMIA
Scientific Chair: Önder Arslan (Ankara University, Turkey), Dieter Hoelzer (Goethe University of Frankfurt, Germany)
Immunotherapies in B-Lineage ALL: Dieter Hoelzer (Goethe University of Frankfurt, Germany)
Current Status and Future Prospects in T-ALL: Nicolas Boissel (Hôpital Saint-Louis, France)
Progress in Ph+/Ph-like ALL: Oliver Ottmann (Cardiff University, Wales)
19:30 – 20:00 BREAK
20:00 – 21:30 SESSION-10
AGGRESSIVE LYMPHOMAS
Scientific Chair: Burhan Ferhanoğlu (Koç University, Turkey)Martin Dreyling (Munich University, Germany)
Primary CNS Lymphoma: Andres Ferreri (Vita-Salute San Raffaele University, Italy)
Mantle Cell Lymphoma: Martin Dreyling (Munich University, Germany)
CAR T-Cells in DLBCL: Marion Subklewe (Gene Center, Germany)
21:30 – 21:45 BREAK
21:45 – 22:00 Closing Remarks